November 16, 2006 -- Pharmion bought privately held Cabrellis and its cancer drug for a price of up to $104 million; Advinus partnered up with Merck to discover metabolic disorder drugs; VaxGen received a one-month extension to resolve the clinical hold on its anthrax vaccine; Dendreon placed 9.9 million shares, raising $45 million; Genzyme said Renagel improved outcomes in dialysis patients; CuraGen and TopoTarget began another trial of PXD101, this time for myelodysplastic syndromes; and Oscient implemented a 1-for-8 reverse split. The Centient Biotech 200™ rose 12 points to 3983, a gain of .31%. More details...
